190 related articles for article (PubMed ID: 23146362)
1. Analytical lessons learned from selected therapeutic protein drug comparability studies.
Federici M; Lubiniecki A; Manikwar P; Volkin DB
Biologicals; 2013 May; 41(3):131-47. PubMed ID: 23146362
[TBL] [Abstract][Full Text] [Related]
2. Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry.
Leurs U; Mistarz UH; Rand KD
Eur J Pharm Biopharm; 2015 Jun; 93():95-109. PubMed ID: 25791210
[TBL] [Abstract][Full Text] [Related]
3. Probing protein interactions with hydrogen/deuterium exchange and mass spectrometry-a review.
Percy AJ; Rey M; Burns KM; Schriemer DC
Anal Chim Acta; 2012 Apr; 721():7-21. PubMed ID: 22405295
[TBL] [Abstract][Full Text] [Related]
4. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy.
Amezcua CA; Szabo CM
J Pharm Sci; 2013 Jun; 102(6):1724-1733. PubMed ID: 23568791
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the quality and structural integrity of a complex glycoprotein mixture following extraction from the formulated biopharmaceutical drug product.
Liu C; Dong S; Xu XJ; Yin Y; Shriver Z; Capila I; Myette J; Venkataraman G
J Pharm Biomed Anal; 2011 Jan; 54(1):27-36. PubMed ID: 20800406
[TBL] [Abstract][Full Text] [Related]
6. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.
Katsila T; Siskos AP; Tamvakopoulos C
Mass Spectrom Rev; 2012; 31(1):110-33. PubMed ID: 21698655
[TBL] [Abstract][Full Text] [Related]
7. Particles in therapeutic protein formulations, Part 1: overview of analytical methods.
Zölls S; Tantipolphan R; Wiggenhorn M; Winter G; Jiskoot W; Friess W; Hawe A
J Pharm Sci; 2012 Mar; 101(3):914-35. PubMed ID: 22161573
[TBL] [Abstract][Full Text] [Related]
8. Analytical aspects of biosimilarity issues of protein drugs.
Kálmán-Szekeres Z; Olajos M; Ganzler K
J Pharm Biomed Anal; 2012 Oct; 69():185-95. PubMed ID: 22633839
[TBL] [Abstract][Full Text] [Related]
9. High throughput screening of protein formulation stability: practical considerations.
Capelle MA; Gurny R; Arvinte T
Eur J Pharm Biopharm; 2007 Feb; 65(2):131-48. PubMed ID: 17107777
[TBL] [Abstract][Full Text] [Related]
10. Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry.
Smith DL; Deng Y; Zhang Z
J Mass Spectrom; 1997 Feb; 32(2):135-46. PubMed ID: 9102198
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
[TBL] [Abstract][Full Text] [Related]
12. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
[TBL] [Abstract][Full Text] [Related]
13. Analytical strategies for identifying drug metabolites.
Prakash C; Shaffer CL; Nedderman A
Mass Spectrom Rev; 2007; 26(3):340-69. PubMed ID: 17405144
[TBL] [Abstract][Full Text] [Related]
14. Forced degradation of therapeutic proteins.
Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms.
Tomar RS; Joseph TJ; Murthy AS; Yadav DV; Subbaiah G; Krishna Reddy KV
J Pharm Biomed Anal; 2004 Sep; 36(1):231-5. PubMed ID: 15351071
[TBL] [Abstract][Full Text] [Related]
16. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
[TBL] [Abstract][Full Text] [Related]
17. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
[TBL] [Abstract][Full Text] [Related]
18. Product development issues for PEGylated proteins.
Payne RW; Murphy BM; Manning MC
Pharm Dev Technol; 2011 Oct; 16(5):423-40. PubMed ID: 20858059
[TBL] [Abstract][Full Text] [Related]
19. [Analytical methodology for drug-protein binding studies].
Zhou D; Li L; Li F
Se Pu; 2004 Mar; 22(2):116-20. PubMed ID: 15712865
[TBL] [Abstract][Full Text] [Related]
20. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.
Houde D; Berkowitz SA; Engen JR
J Pharm Sci; 2011 Jun; 100(6):2071-86. PubMed ID: 21491437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
